Literature DB >> 16496414

Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro.

Veronica Yao1, Dean J Bacich.   

Abstract

BACKGROUND: Prostate specific membrane antigen (PSMA) expression is correlated with stage and grade of prostate cancer suggesting that it confers a growth advantage. We studied if PSMA folate hydrolase activity provides cells a growth advantage in a low folate (LF) micro-environment by hydrolyzing extracellular poly-gamma-glutamated folate to a form that cells can import.
METHODS: Proliferation of LNCaP and DU-145 cells was assessed in media containing low (LF), physiological (PF), or high (HF) folate with or without penta-gamma-glutamated folate and a PSMA specific folate hydrolase inhibitor, 2-(phosphonomethyl)-pentanedioic acid (2-PMPA).
RESULTS: LNCaP cells, which express PSMA, and DU-145 cells, which do not, displayed decreased proliferation when grown in LF or PF compared to HF media. This reduction in proliferation was eliminated in LNCaP cells when penta-gamma-glutamated folate was added to the media. In the presence of penta-gamma-glutamated folic acid DU-145 cells displayed increased growth but this was still significantly lower than growth in HF medium. Addition of 2-PMPA attenuated the increased growth seen in LNCaP cells but had no effect on DU-145 cell growth.
CONCLUSIONS: The folate hydrolase activity of PSMA may provide a growth advantage in LF and PF environments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16496414     DOI: 10.1002/pros.20361

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  22 in total

Review 1.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 2.  The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.

Authors:  Benjamin T Ristau; Denise S O'Keefe; Dean J Bacich
Journal:  Urol Oncol       Date:  2013-12-08       Impact factor: 3.498

Review 3.  PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

Authors:  Ronnie C Mease; Catherine A Foss; Martin G Pomper
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

Review 4.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

5.  PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer.

Authors:  Leslie Ann Caromile; Kristina Dortche; M Mamunur Rahman; Christina L Grant; Christopher Stoddard; Fernando A Ferrer; Linda H Shapiro
Journal:  Sci Signal       Date:  2017-03-14       Impact factor: 8.192

6.  Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT.

Authors:  Johannes Schwenck; Hansjoerg Rempp; Gerald Reischl; Stephan Kruck; Arnulf Stenzl; Konstantin Nikolaou; Christina Pfannenberg; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-24       Impact factor: 9.236

Review 7.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

8.  Folic acid and risk of prostate cancer: results from a randomized clinical trial.

Authors:  Jane C Figueiredo; Maria V Grau; Robert W Haile; Robert S Sandler; Robert W Summers; Robert S Bresalier; Carol A Burke; Gail E McKeown-Eyssen; John A Baron
Journal:  J Natl Cancer Inst       Date:  2009-03-10       Impact factor: 13.506

9.  Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology.

Authors:  Daniel W Binzel; Yi Shu; Hui Li; Meiyan Sun; Qunshu Zhang; Dan Shu; Bin Guo; Peixuan Guo
Journal:  Mol Ther       Date:  2016-04-29       Impact factor: 11.454

10.  Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis.

Authors:  Veronica Yao; Anil Parwani; Christoph Maier; Warren DeWayne Heston; Dean John Bacich
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.